APOA1 and metabolic dysfunction-associated steatohepatitis: After PGBF treatment, C4 and ApoA1 were increased vs. control, and associated with decreases in the LDL/HDL ratio, suggesting that PGBF-associated changes in BA metabolism may contribute to an improvement in lipoprotein profiles that could possibly lead to a reduction in cardiovascular risk in patients with NASH [96,97].